Autres langues Bionomics Australian S.E.

Actions

BNO

AU000000BNO5

Temps Différé Australian S.E. Autres places de cotation 08:10:06 24/08/2023			Varia. 5j.	Varia. 1 janv.
0,01 ^AUD	-.--%		-.--%	-.--%

21/03	Bionomics annonce les résultats de l'analyse de l'ensemble des données de l'essai de phase 2b ATTUNE portant sur le BNC210 chez des patients souffrant de troubles de stress post-traumatique	CI
15/03	Bionomics Limited annonce ses résultats pour le semestre clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	21/03
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder	21/03
Bionomics : Notes to the Consolidated Financial Statements - Form 6-K	15/03
Bionomics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	15/03
Bionomics to Present at the 2024 BIO CEO & Investor Conference	22/02
Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVL	29/01
Wall Street Set to Open Higher in Monday Trading Ahead of Economic Indicators Data	22/01
US Futures Poised to Open Week Higher, Leading Economic Indicators on Tap	22/01
Bionomics Provides a Review of 2023 and of 2024 Plans	22/01
Bionomics to Present at Biotech Showcase™ 2024	05/01
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting	06/12
Bionomics : Results of Annual General Meeting - Form 6-K	30/11
Bionomics : • Operations Presentation	30/11
Bionomics : Announces Retirement of Board Member - Form 6-K	28/11
Bionomics Limited Announces Retirement of Dr. Errol De Souza as Board of Directors, Effective November 30, 2023	28/11
Bionomics : Announces Retirement of Board Member	28/11
ADRs End Higher, Yoshitsu Co. Ltd. Climbs 19.2%	10/11
Bionomics : Notice of Annual General Meeting Explanatory Statement and Proxy Form - Form 6-K	03/11
Bionomics to Advance Social Anxiety Disorder Treatment Into Phase 3 Studies After End-of-Phase 2 Meeting With US FDA	16/10/23
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder	16/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Bionomics Australian S.E.

Actions

BNO

AU000000BNO5

Autres langues

Filtres